Stocks · Healthcare · Biotechnology
BioMarin Pharmaceutical Inc. BMRN
$57.54 +0.63% Close, Oct 5, 2026 · NASDAQ · Market cap $11.05B
Next earnings report: Oct 26, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.39, down 88.4% year over year.
- Operating margin narrowed to 8.0% from 25.3% a year earlier.
- Net debt is 8.6× EBITDA, a high level of leverage.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 45%
- EPS growth (TTM, YoY)Bottom 19%
- FCF growth (TTM, YoY)Bottom 46%
- Revenue growth, 3-year CAGRTop 38%
- Revenue growth accelerationTop 34%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 31%
- Gross marginTop 36%
- Operating marginTop 30%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 50%
- Net debt / EBITDA (lower is better)Bottom 7%
- Interest coverTop 31%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 28%
- Free-cash-flow yieldTop 13%
- EBITDA / enterprise valueTop 31%
- Sales / enterprise valueTop 49%
- P/E vs own 5-year history (lower is better)Bottom 31%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 50%
- 6-month returnBottom 44%
- 1-year return vs S&P 500Bottom 45%
- Distance from 52-week highTop 31%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 13%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 39%
- Upside to consensus price targetBottom 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 9%
- Maximum drawdown, 3 yearsTop 23%
- Beta vs S&P 500 (lower is better)Top 17%
- Net debt / EBITDA (lower is better)Bottom 7%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 9.9% | 11.2% | ↑ |
| EPS growth (YoY) | -48.3% | -88.4% | ↓ |
| Gross margin | 79.6% | 75.5% | ↓ |
| Operating margin | 25.3% | 8.0% | ↓ |
| FCF margin | 22.6% | 21.5% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 11.2% | 9.9% | ↑ | Top 45% |
| EPS growth (TTM, YoY) | -88.4% | -48.3% | ↓ | Bottom 19% |
| Gross margin | 75.5% | 79.6% | ↓ | Top 36% |
| Operating margin | 8.0% | 25.3% | ↓ | Top 30% |
| Net margin | 2.1% | 21.5% | ↓ | — |
| Free-cash-flow margin | 21.5% | 22.6% | ↓ | — |
| Return on invested capital | 1.2% | — | Top 31% | |
| Revenue growth, 3-year CAGR | 15.4% | — | Top 38% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.3%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +12.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 8.63×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 3.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.22%
- Shareholder yield
- 0.22%
- Share count change, 1 year
- -1.3%
- Share count change, 3-year CAGR
- -0.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -56.0%
- Average 2-day reaction, last 8
- +0.4%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $90.88
- Target vs current price
- +57.9%
- Analysts with a rating
- 41
- Share rating Buy or Strong Buy
- 71%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +26.7% | +2.6% | +17.2% | +11.8% | — |
| May 4, 2026 | -2.6% | +2.6% | +0.0% | +1.8% | +13.5% |
| Feb 23, 2026 | -241.7% | -1.8% | -3.7% | -15.5% | -22.5% |
| Oct 27, 2025 | -6.7% | -3.3% | -1.7% | +0.4% | +5.0% |
| Aug 4, 2025 | +42.9% | +3.7% | -1.4% | +0.2% | -9.4% |
| May 1, 2025 | +35.9% | -1.5% | -6.9% | -8.1% | -8.7% |
| Feb 19, 2025 | +18.5% | +1.2% | +9.7% | +10.3% | -9.5% |
| Oct 29, 2024 | +3.6% | -0.3% | -5.9% | -7.2% | -11.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $1.20 | $0.95 | +26.7% | $989.7M |
| May 4, 2026 | $0.76 | $0.78 | -2.6% | $766.0M |
| Feb 23, 2026 | -$0.24 | $0.17 | -241.7% | $874.6M |
| Oct 27, 2025 | -$0.16 | -$0.15 | -6.7% | $776.1M |
| Aug 4, 2025 | $1.23 | $0.86 | +42.9% | $825.0M |
| May 1, 2025 | $0.97 | $0.71 | +35.9% | $745.1M |
| Feb 19, 2025 | $0.64 | $0.54 | +18.5% | $747.0M |
| Oct 29, 2024 | $0.55 | $0.53 | +3.6% | $745.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 147.5× | 89.6× | 65th | Top 28% |
| P/E (forward) | 11.5× | — | — | — |
| EV / EBITDA | 37.3× | — | — | Top 31% |
| EV / Sales | 4.22× | — | — | Top 49% |
| Free-cash-flow yield | 6.63% | — | — | Top 13% |
| Earnings yield | 0.68% | — | — | Top 28% |
P/E over the past five years
Range 17.9× – 478.5× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +3.5%
- Earnings per share growth (TTM)
- -88.4%
- Change in P/E multiple
- +757.4%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.2%
- 200-day average slope (20 days)
- +1.5%
- Distance from 50-day average
- -10.0%
- Distance from 200-day average
- -2.0%
- RSI (14)
- 28.9
- Relative volume
- 1.19×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 29.9%
- Volatility vs own 5-year history
- 43th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.52
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -18.1%
- Maximum drawdown, 3 years
- -49.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 27, 2023 | May 18, 2026 | -57.6% | 828 days | Not yet recovered |
| Feb 16, 2022 | Jun 14, 2022 | -22.9% | 81 days | 35 days (Aug 4, 2022) |
| Jan 7, 2021 | Oct 27, 2021 | -20.9% | 203 days | 17 days (Nov 19, 2021) |
| Aug 15, 2022 | Nov 9, 2022 | -16.5% | 61 days | 10 days (Nov 23, 2022) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $11.05B
- P/E (TTM)
- 147.5
- EPS, diluted (TTM)
- $0.39
- Revenue (TTM)
- $3.41B
- 52-week range
- $49.26 – $70.98
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Gross profit | $1.38B | $1.59B | $1.89B | $2.27B | $2.48B |
| Operating income | -$82.3M | $161.0M | $185.8M | $484.2M | $533.5M |
| Net income | -$64.1M | $141.6M | $167.6M | $426.9M | $348.9M |
| EPS (diluted) | -$0.35 | $0.75 | $0.88 | $2.21 | $1.80 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $745.7M | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M | $766.2M | $989.7M |
| Net income | $106.1M | $124.9M | $185.7M | $240.5M | -$30.7M | -$46.6M | $105.5M | $44.8M |
| EPS (diluted) | $0.55 | $0.64 | $0.95 | $1.23 | -$0.16 | -$0.22 | $0.54 | $0.23 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M |
| Capital expenditure | -$119.2M | -$121.0M | -$107.6M | -$97.4M | -$103.0M |
| Free cash flow | $185.3M | $54.9M | $51.6M | $475.4M | $725.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $69.3M | $69.4M | $0 | $14.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $874.0M
- Total assets
- $11.72B
- Total liabilities
- $5.40B
- Total debt
- $4.20B
- Net debt
- $3.33B
- Shareholders’ equity
- $6.32B
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 10,075,655
- Days to cover
- 5.53
- Change vs previous report
- +2.0%
FINRA short interest, settlement date Sep 15, 2026.